29 results on '"Biglietto M"'
Search Results
2. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
3. Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
4. Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
5. Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by next generation sequencing (NGS) in the CAPRI- GOIM trial
6. Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial
7. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
8. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
9. Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study
10. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
11. LBA-09 Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab
12. Anemia management with epoetin beta in anemic patients with cancer receiving chemotherapy: Pananemia observational study on clinical practice.
13. The therapy of kidney cancer with biomolecular drugs
14. Bi-weekly administration of capecitabine + oxaliplatin (Xelox-2) in first-line treatment of advanced colorectal cancer (ACRC): A phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)
15. Target therapy in metastatic renal cell carcinoma
16. Biweekly irinotecan (IRI) with 6s-folinic acid (FA)-modulated 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC): a phase III study
17. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG)
18. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II–III randomized trial
19. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck
20. Docetaxel (DTX) + cisplatin (CDDP) in locally advanced or metastatic head and neck cancer (HN). A phase II study
21. Determination of cyclophosphamide and ifosphamide in urine at trace levels by gas chromatography/tandem mass spectrometry
22. A phase I study of cisplatin, methotrexate, levofolinic acid and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck
23. Biweekly administration of methotrexate (MTX), levofolinic acid (LFA), and 5-fluorouracil (5-FU) in advanced colorectal carcinomas
24. Phase II trial of paclitaxel (P) and cisplatin (COOP) in patients with advanced breast cancer refractory to anthracycline (A) therapy
25. Protracted infusion (PI) of 5-FU+FA in advanced colorectal cancer
26. Urinary metabolites of PGIα in patients with osteosarcoma
27. A phase II study of octreotide in metastatic advanced prostatic cancer (MAPC)
28. Sandostatin, a long acting somatostatin analogue, in the treatment of advanced metastatic prostatic cancer
29. Lonidamine Alone and in Combination with Other Chemotherapeutic Agents in the Treatment of Cancer Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.